about
Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st centuryNeuroprotection by spice-derived nutraceuticals: you are what you eat!Nutraceuticals in Parkinson's DiseaseHeterologous production of curcuminoidsEvaluation of traditional medicines for neurodegenerative diseases using Drosophila modelsn-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's diseaseModulating self-assembly of amyloidogenic proteins as a therapeutic approach for neurodegenerative diseases: strategies and mechanismsCurcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model.A novel "molecular tweezer" inhibitor of α-synuclein neurotoxicity in vitro and in vivo.Oxidative toxicity in neurodegenerative diseases: role of mitochondrial dysfunction and therapeutic strategies.Curcumin prevents formation of polyglutamine aggregates by inhibiting Vps36, a component of the ESCRT-II complex.β-dicarbonyl enolates: a new class of neuroprotectants.Epidemiology of Parkinson disease in the city of Kolkata, India: a community-based studyCyclin-G-associated kinase modifies α-synuclein expression levels and toxicity in Parkinson's disease: results from the GenePD Study.A multi-pathway perspective on protein aggregation: implications for control of the rate and extent of amyloid formation.The effect of curcumin on human islet amyloid polypeptide misfolding and toxicity.Curcumin Treatment Improves Motor Behavior in α-Synuclein Transgenic MiceEffect of EGCG on Fe(III)-induced conformational transition of silk fibroin, a model of protein related to neurodegenerative diseases.Curcumin prevents aggregation in α-synuclein by increasing reconfiguration rate.Disordered binding of small molecules to Aβ(12-28).Stabilizing Off-pathway Oligomers by Polyphenol Nanoassemblies for IAPP Aggregation InhibitionCurcumin and neurodegenerative diseases.Protein folding and aggregation into amyloid: the interference by natural phenolic compoundsPotential Role of Caffeine in the Treatment of Parkinson's Disease.Botanical phenolics and brain healthPersistent short-term memory defects following sleep deprivation in a drosophila model of Parkinson disease.Molecular chaperones and associated cellular clearance mechanisms against toxic protein conformers in Parkinson's disease.Drug targets from genetics: α-synuclein.Curcumin and neurodegenerative diseases: a perspective.Rottlerin and curcumin: a comparative analysis.Monoamine oxidase and α-synuclein as targets in Parkinson's disease therapy.Natural polyphenols binding to amyloid: a broad class of compounds to treat different human amyloid diseases.Clinical development of curcumin in neurodegenerative disease.Structural, morphological, and functional diversity of amyloid oligomers.Lifestyle Modulators of Neuroplasticity: How Physical Activity, Mental Engagement, and Diet Promote Cognitive Health during Aging.Investigational α-synuclein aggregation inhibitors: hope for Parkinson's disease.Anti-amyloid compounds inhibit α-synuclein aggregation induced by protein misfolding cyclic amplification (PMCA)Curcumin modulates α-synuclein aggregation and toxicity.Chronic dietary supplementation with turmeric protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-mediated neurotoxicity in vivo: implications for Parkinson's disease.Effect of curcumin analogs onα-synuclein aggregation and cytotoxicity.
P2860
Q24630927-E11F449D-EF77-480C-A49E-EC335BB5F3C4Q24635358-EC3B184A-ADA8-47EA-BA28-C317F356E16BQ26752769-C5968E4D-A987-4393-A580-39450022CB9FQ26824008-9AEE94FC-DB7D-4BDB-AEEF-51E4E49232EDQ27027455-BF419597-DE9C-4D99-B95A-ED94C9E0C348Q27334018-82078270-45D9-4A42-A3CB-7173206E915DQ28259424-DF57E0C2-4042-43A3-B9C2-A1A47EE5D387Q33569173-DD95E22B-ABEA-433D-AF8B-B5284831C171Q34030874-56172DE4-7FC0-4D8B-A133-B7F3234F237DQ34203215-6C7128DF-C200-48BA-A87E-60B996713C77Q34374859-D43C6B9A-AD0A-4DA8-9DF8-BA098DCB5DE7Q34388443-3A6A36AE-DC38-4135-8647-493BB3BE18C8Q34455118-5067D606-7C1D-4294-A98E-8E40C042AC8AQ34718087-8B066447-A1C8-4F0D-8CF1-E98B7BDAF8AFQ35146724-95D89DF8-39CF-410B-A556-266E727FAAB7Q35383488-AAE22A86-CB6F-4C91-BAAB-6B945049B159Q35650069-F5A87E21-475E-45D5-88CB-1785B5FDF676Q35809943-8D8B7D52-871C-4105-9542-D4F109A67CE4Q35841861-049C6FA3-ABBB-4F7A-A383-CC2BD8F23B90Q35842197-D8308610-1BF2-415C-B057-D3DA79B3CCDEQ36499539-ADF3BCE5-0B05-4762-80DE-4BE02C0BC635Q36625852-1B089962-0C00-44CC-BDFF-90407E25540CQ37007345-21FF753D-650C-477E-9290-D388001A50E9Q37129378-CCE971D6-E2D1-4D3C-B31F-26B2B48833BFQ37192900-C4E8361B-2291-4298-AB56-B6BBB203639FQ37279139-ABD0839F-03F0-4E22-AD99-9577E9559233Q37853789-7A016A5E-D0B3-4416-A11F-088F071098D7Q37916635-5AC12064-89C6-4622-A1D9-9F41E5DB63FFQ38016212-6E3C2DA7-3E78-4747-BCBD-6124D994D8DFQ38023565-57FB9075-35CD-480D-BB7B-B30D99E186D1Q38213838-FED3A42A-A9A7-43B8-A980-28CF381947FBQ38244247-3EBD20BD-1D40-4AD9-B00E-845BCD567C07Q38513024-8C774447-FF12-4E6D-B2D9-14C9330F06ECQ38549882-B8609E41-1122-4E63-B56E-6BB0778A9489Q38659686-9A66D08E-8414-4C05-8099-7A34115517F8Q38817063-03E9D630-2917-41D6-8794-E31AF375E29FQ39006845-EC04EC24-BDD3-45BB-9410-EFC5AD096494Q39178579-9B695498-BD30-413D-ACAC-3DCE79ED14E7Q39267846-C9DA1FAD-335C-4494-A788-9565E664D9B7Q39659132-CBFB66D7-F886-42AC-8B3B-BFA138EC4D47
P2860
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Curcumin inhibits aggregation of alpha-synuclein.
@ast
Curcumin inhibits aggregation of alpha-synuclein.
@en
Curcumin inhibits aggregation of alpha-synuclein.
@nl
type
label
Curcumin inhibits aggregation of alpha-synuclein.
@ast
Curcumin inhibits aggregation of alpha-synuclein.
@en
Curcumin inhibits aggregation of alpha-synuclein.
@nl
prefLabel
Curcumin inhibits aggregation of alpha-synuclein.
@ast
Curcumin inhibits aggregation of alpha-synuclein.
@en
Curcumin inhibits aggregation of alpha-synuclein.
@nl
P2093
P1476
Curcumin inhibits aggregation of alpha-synuclein.
@en
P2093
James E Galvin
Jeffrey Strider
Neeraj Pandey
William C Nolan
P2888
P304
P356
10.1007/S00401-007-0332-4
P50
P577
2008-01-10T00:00:00Z
P6179
1043633191